In recent studies by us and other groups, Toll-like receptor 7 (TLR7) agonist imiquimod (R837) and TLR9 agonist CpG oligodeoxynucleotides (CpG-ODNs) could help make the tumor into an “in situ vaccine” after intratumoral administration with them at low doses, greatly enhancing antitumor immune responses and inhibiting both treated and distant tumors lesions [13, 14]. The gene discussed is TLR7; the disease is neoplasm.